On May 26, 2022 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Puma Biotechnology, MAY 26, 2022, View Source [SID1234615136]). The ASCO (Free ASCO Whitepaper) Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 3 – 7, 2022. The corresponding abstracts of the two posters that Puma will be presenting are now live on the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting website. The full posters will be available on the Puma website following the presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Full abstracts of the following posters are available online at: ASCO (Free ASCO Whitepaper).org/abstracts.
Poster Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Abstract 4079: Targeting HER2 mutation-positive advanced biliary tract cancers with neratinib: final results from the phase 2 SUMMIT ‘basket’ trial
JJ Harding, S Piha-Paul, RH Shah, JM Cleary, D Quinn, I Braña, V Moreno, M Borad, S Loi, I Spanggaard, J Ford, D DiPrimeo, MF Berger, LD Eli, F Meric-Bernstam, DB Solit, GK Abou-Alfa
Presenter: James J. Harding, MD | Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College
Date/Time: June 4, 2022, at 9:00 am ET
Poster Session: Breast Cancer—Metastatic
Abstract 1028: Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial
K Jhaveri, JW Goldman, SA Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, ES Yang, I Spanggaard, S Reid, M Burkard, A Prat, S Loi, J Crown, A Hanker, C Ma, R Bose, LD Eli, H Wildiers
Presenter: Komal L. Jhaveri, FACP, MD | Memorial Sloan Kettering Cancer Center
Date/Time: June 6, 2022, at 9:00 am ET